Name | Glucagon (19-29), human acetate |
Description | Glucagon (19-29), human acetate a COOH-terminal fragment processed from glucagon, is a potent and efficient inhibitor of insulin secretion. |
In vitro | At concentrations ranging from 0.01 to 1000 pM, glucagon 19-29 dose-dependently (ID50 = 1 pM) inhibited by 80-100% the insulin release triggered by glucose, glucagon, glucagon-like peptide-1-(7-36) amide (tGLP-1), or glibenclamide, but not that induced by carbachol[1]. |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Keywords | Glucagon , human Acetate | Glucagon (1929), human acetate | Glucagon (19 29), human acetate |
Inhibitors Related | Tirzepatide Acetate(2023788-19-2 free base) | PF-06882961 Tris | PF-06882961 | Glucagon (1-29), bovine, human, porcine hydrochloride | (S, R)-LSN 3318839 | NNC 92-1687 | Adomeglivant | 6α-Methylprednisolone 21-hemisuccinate sodium salt | Orforglipron | LSN3318839 |
Related Compound Libraries | Bioactive Compound Library | Peptide Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |